NCCN’s LEAP Working Group monitors the delivery of the Late Effects Assessment Programme (LEAP) and provides recommendations for improvements. LEAP focuses on patients who have completed treatment and the bulk of their disease surveillance programme. It deals with the consequences of the treatment which was necessary to achieve cure of the cancer. This includes evaluating treatment related organ system dysfunction, reintegration into the community, and surveillance for second malignancy.